Anemia Control in Renal Transplant Recipients Receiving Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment: The AnemiaTrans Study

Autor: Ana I, Sánchez-Fructuoso, Juan C, Ruiz, José V, Torregrosa, Esther, González, Ernesto, Gómez, Roberto J, Gallego, María I, Troya, Carlos, Jimenez, Francisco, Llamas, Rafael, Romero, Carmen, Bernis, José F, Crespo, Luis, Guirado, C, Facundo
Rok vydání: 2012
Předmět:
Adult
Male
Safety Management
medicine.medical_specialty
Time Factors
Anemia
Injections
Subcutaneous
Clinical practice
Erythropoiesis-stimulating agent-naive
Risk Assessment
Severity of Illness Index
Renal transplant recipients
Gastroenterology
Drug Administration Schedule
Polyethylene Glycols
Cohort Studies
Hemoglobins
Continuous erythropoietin receptor activator
hemic and lymphatic diseases
Internal medicine
Severity of illness
Humans
Medicine
Pharmacology (medical)
Hemoglobin
Erythropoietin
Retrospective Studies
Postoperative Care
Dose-Response Relationship
Drug
business.industry
Erythropoiesis-stimulating agents
Retrospective cohort study
General Medicine
Middle Aged
medicine.disease
Kidney Transplantation
Rheumatology
Treatment Outcome
Spain
Immunology
Kidney Failure
Chronic
Female
business
Follow-Up Studies
Cohort study
Kidney disease
Zdroj: ADVANCES IN THERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 1865-8652
0741-238X
DOI: 10.1007/s12325-012-0063-3
Popis: Introduction: Continuous erythropoietin receptor activator (C.E.R.A.) effectively enables anemia control in patients with chronic kidney disease, but little information is available in renal transplant recipients. The authors aimed to evaluate the effect of C.E.R.A. under clinical practice conditions on anemia control in renal transplant recipients. Methods: This was a multicenter, retrospective, observational study carried out in adult renal transplant patients in the immediate posttransplant period and at late posttransplant period receiving C.E.R.A. in clinical practice. Patients' data were retrieved from their medical charts at baseline and months 1, 3, and 6. Results: A total of 318 evaluable patients were enrolled into the study: 32 in the immediate posttransplant period and 286 at late posttransplant period (erythropoiesisstimulating agent [ESA]-na < ve, n = 44; converting from other ESAs, n = 242). Patients in the immediate posttransplant period experienced a significant increase in hemoglobin (Hb) levels from baseline to month 1 (9.9 +/- 1.5 g/dL vs. 11.5 +/- 1.4 g/dL; P < 0.001). ESA-na < ve patients showed increasing mean Hb levels from baseline to month 6 (10.1 +/- 0.7 g/dL vs. 11.7 +/- 1.0 g/dL; P < 0.001) and 94.7% achieved Hb a parts per thousand yen11 g/dL during the study. In patients converted from other ESAs, the percentage of patients with Hb between 11-13 g/dL was maintained from baseline to month 6 with no significant differences (61.0% vs. 62.4%). Mean monthly doses of C.E.R.A. at baseline were 134.4 +/- 56.4 mu g, 81.3 +/- 28.1 mu g, and 93.0 +/- 44.2 mu g in immediate posttransplant, ESA-na < ve, and converted patients, respectively. C.E.R.A. was well tolerated. Conclusion: C.E.R.A. enables anemia control in renal transplant recipients, allowing target Hb levels to be achieved and maintained with doses even below those described in the Summary of Product Characteristics.
Databáze: OpenAIRE
Externí odkaz: